These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 355121

  • 1. Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor.
    Rumjanek VM, Brent L, Pepys MB.
    Immunology; 1978 Jun; 34(6):1117-23. PubMed ID: 355121
    [Abstract] [Full Text] [Related]

  • 2. Regulation of transplantation immunity in vivo by monoclonal antibodies recognizing host class II restriction elements. II. Effects of anti-Ia immunotherapy on host T cell responses to graft alloantigens.
    Williams IR, Perry LL.
    J Immunol; 1985 May; 134(5):2942-7. PubMed ID: 3156920
    [Abstract] [Full Text] [Related]

  • 3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 4. Delayed hypersensitivity reactions to Listeria monocytogenes in rats decomplemented with cobra factor and in C5-deficient mice.
    Jungi TW, Pepys MB.
    Immunology; 1981 Jun; 43(2):271-9. PubMed ID: 6788681
    [Abstract] [Full Text] [Related]

  • 5. Effect of decomplementation with cobra venom factor on the passive immunological enhancement of mouse skin allografts.
    Hutchinson IV, Brent L.
    Transplantation; 1982 Jul; 34(1):64-7. PubMed ID: 6750879
    [No Abstract] [Full Text] [Related]

  • 6. Active suppression of host-vs-graft reaction in pregnant mice. VI. Soluble suppressor activity obtained from decidua of allopregnant mice blocks the response to IL 2.
    Clark DA, Chaput A, Walker C, Rosenthal KL.
    J Immunol; 1985 Mar; 134(3):1659-64. PubMed ID: 3871455
    [Abstract] [Full Text] [Related]

  • 7. T cell subsets in the immune rejection of murine heterotopic corneal allografts.
    Matoba AY, Peeler JS, Niederkorn JY.
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1244-54. PubMed ID: 2942516
    [Abstract] [Full Text] [Related]

  • 8. Prolonged cardiac allograft survival in presensitized rats after a high activity Yunnan-cobra venom factor therapy.
    Li R, Chen G, Guo H, Wang DW, Xie L, Wang SS, Wang WY, Xiong YL, Chen S.
    Transplant Proc; 2006 Dec; 38(10):3263-5. PubMed ID: 17175243
    [Abstract] [Full Text] [Related]

  • 9. Immunomodulation by an inhibitor of S-adenosyl-L-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses.
    Wolos JA, Frondorf KA, Babcock GF, Stripp SA, Bowlin TL.
    Cell Immunol; 1993 Jul; 149(2):402-8. PubMed ID: 8330316
    [Abstract] [Full Text] [Related]

  • 10. Survival of cytotoxic T-cell clones (Tc) in vivo and their ability to effect skin allograft rejection in T-cell depleted mice.
    Berens ES, Shelton MW, Walp LA, Basler JT, Hanto DW.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):138-9. PubMed ID: 2650095
    [No Abstract] [Full Text] [Related]

  • 11. Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.
    Shaw JO, Roberts MF, Ulevitch RJ, Henson P, Dennis EA.
    Am J Pathol; 1978 Jun; 91(3):517-30. PubMed ID: 655262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of anticomplementary cobra venom factor on hyperacute rat cardiac allograft rejection.
    Forbes RD, Pinto-Blonde M, Guttmann RD.
    Lab Invest; 1978 Nov; 39(5):463-70. PubMed ID: 366280
    [Abstract] [Full Text] [Related]

  • 16. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [Abstract] [Full Text] [Related]

  • 17. The in vivo activity of in vitro immunized mouse thymocytes. II. Rejection of skin allografts and graft-vs-host activity.
    Rouse BT, Wagner H.
    J Immunol; 1972 Dec; 109(6):1282-9. PubMed ID: 4404454
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
    Hummel S, Wilms D, Vitacolonna M, Zöller M.
    J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.